# Inhibrx Biosciences Inc. (INBX)

Source: https://www.quantisnow.com/company/INBX
Generated: 2026-11-19T00:56:07.342Z

- Ticker: INBX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- SEC CIK: 0002007919
- Website: inhibrx.com

## About

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.

## Latest INBX news and filings

- 2026-11-17 22:29 UTC [SEC Form 8-K] [Inhibrx Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inhibrx-biosciences-inc-filed-sec-form-8-k-other-events-financial-6797408)
- 2026-11-17 21:53 UTC [Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma](https://www.quantisnow.com/insight/inhibrx-announces-updated-clinical-data-for-ozekibart-inbrx-109-in-ewing-6797187)
- 2026-11-13 21:30 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inhibrx-biosciences-inc-6790956)
- 2026-11-13 21:25 UTC [SEC Form S-3ASR] [SEC Form S-3ASR filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-3asr-filed-by-inhibrx-biosciences-inc-6790848)
- 2026-11-13 21:12 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-inhibrx-biosciences-inc-6790658)
- 2026-11-13 21:08 UTC [SEC Form 8-K] [Inhibrx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inhibrx-biosciences-inc-filed-sec-form-8-k-results-of-operations-6790578)
- 2026-11-13 21:02 UTC [Earnings] [Inhibrx Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/inhibrx-reports-third-quarter-2026-financial-results-6790373)
- 2026-10-28 17:34 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inhibrx-biosciences-inc-6761008)
- 2026-10-14 22:58 UTC [Insider Buy] [Chief Executive Officer Lappe Mark bought $17,152 worth of shares (200 units at $85.76) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-lappe-mark-bought-17152-worth-of-shares-6746996)
- 2026-10-13 20:00 UTC [Inhibrx Announces Participation in Upcoming Scientific Conferences](https://www.quantisnow.com/insight/inhibrx-announces-participation-in-upcoming-scientific-conferences-6744904)
- 2026-09-28 21:47 UTC [Insider Buy] [Chief Executive Officer Lappe Mark bought $998,784 worth of shares (10,000 units at $99.88) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-lappe-mark-bought-998784-worth-of-shares-6728097)
- 2026-09-28 21:03 UTC [SEC Form 8-K] [Inhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inhibrx-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-6728000)
- 2026-09-23 20:59 UTC [Insider Buy] [Director Kayyem Jon Faiz bought $500,000 worth of shares (5,000 units at $100.00) (SEC Form 4)](https://www.quantisnow.com/insight/director-kayyem-jon-faiz-bought-500000-worth-of-shares-5000-6724394)
- 2026-09-18 20:26 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Forsyth Douglas](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-forsyth-douglas-6720636)
- 2026-09-18 20:25 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Vuori Kristiina Md](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-vuori-kristiina-md-6720629)
- 2026-09-18 20:22 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Manhard Kimberly](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-manhard-kimberly-6720616)
- 2026-09-18 20:20 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Kayyem Jon Faiz](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-kayyem-jon-faiz-6720604)
- 2026-09-17 21:46 UTC [Insider Buy] [Director Kayyem Jon Faiz bought $500,000 worth of shares (5,000 units at $100.00) (SEC Form 4)](https://www.quantisnow.com/insight/director-kayyem-jon-faiz-bought-500000-worth-of-shares-5000-6719684)
- 2026-09-15 21:52 UTC [SEC Form 4] [Director Manhard Kimberly sold $163,542 worth of shares (1,500 units at $109.03) (SEC Form 4)](https://www.quantisnow.com/insight/director-manhard-kimberly-sold-163542-worth-of-shares-1500-units-6716571)
- 2026-09-15 20:02 UTC [SEC Form 144] [SEC Form 144 filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-inhibrx-biosciences-inc-6716003)
- 2026-09-14 20:57 UTC [SEC Form 144] [SEC Form 144 filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-inhibrx-biosciences-inc-6714791)
- 2026-09-11 17:15 UTC [SEC Form 144] [SEC Form 144 filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-inhibrx-biosciences-inc-6712740)
- 2026-09-10 23:06 UTC [SEC Form 4] [Director Manhard Kimberly sold $115,468 worth of shares (1,000 units at $115.47) (SEC Form 4)](https://www.quantisnow.com/insight/director-manhard-kimberly-sold-115468-worth-of-shares-1000-units-6712229)
- 2026-09-09 21:15 UTC [SEC Form 144] [SEC Form 144 filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-inhibrx-biosciences-inc-6710374)
- 2026-09-08 23:59 UTC [SEC Form 144] [SEC Form 144 filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-inhibrx-biosciences-inc-6708898)
- 2026-09-08 21:23 UTC [Insider Buy] [Director Kayyem Jon Faiz bought $567,580 worth of shares (5,000 units at $113.52) (SEC Form 4)](https://www.quantisnow.com/insight/director-kayyem-jon-faiz-bought-567580-worth-of-shares-5000-6708739)
- 2026-09-08 20:26 UTC [Insider Buy] [Director Forsyth Douglas bought $286,617 worth of shares (2,500 units at $114.65) (SEC Form 4)](https://www.quantisnow.com/insight/director-forsyth-douglas-bought-286617-worth-of-shares-2500-units-6708449)
- 2026-09-08 20:04 UTC [Insider Buy] [Chief Executive Officer Lappe Mark bought $2,645,399 worth of shares (25,000 units at $105.82) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-lappe-mark-bought-2645399-worth-of-shares-6708224)
- 2026-09-08 20:01 UTC [SEC Form 8-K] [Inhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inhibrx-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-6708159)
- 2026-09-08 11:30 UTC [Earnings Date] [Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study](https://www.quantisnow.com/insight/inhibrxs-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-6707463)
- 2026-09-04 20:00 UTC [Conference Announcement] [Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study](https://www.quantisnow.com/insight/inhibrx-to-host-webcast-presentation-to-provide-primary-endpoint-results-6706639)
- 2026-08-24 12:35 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Inhibrx Biosciences with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-inhibrx-biosciences-with-a-new-6692232)
- 2026-08-14 21:19 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-inhibrx-biosciences-inc-6683720)
- 2026-08-13 20:10 UTC [SEC Form 8-K] [Inhibrx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inhibrx-biosciences-inc-filed-sec-form-8-k-results-of-operations-6680457)
- 2026-08-13 20:04 UTC [Inhibrx Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/inhibrx-reports-second-quarter-2026-financial-results-6680260)
- 2026-08-13 20:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-inhibrx-biosciences-inc-6680183)
- 2026-08-03 16:26 UTC [SEC Form SCHEDULE 13G filed by Inhibrx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-inhibrx-biosciences-inc-6659263)
- 2026-07-16 20:06 UTC [SEC Form 8-K] [Inhibrx Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inhibrx-biosciences-inc-filed-sec-form-8-k-entry-into-a-6639673)
- 2026-07-16 13:00 UTC [Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million](https://www.quantisnow.com/insight/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-6639294)
- 2026-06-15 20:06 UTC [SEC Form 8-K] [Inhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inhibrx-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-6602530)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/INBX
- Earnings history: https://www.quantisnow.com/earnings/INBX
- Dividend history: https://www.quantisnow.com/dividends/INBX
- Insider transactions: https://www.quantisnow.com/insiders/INBX
- Options chain: https://www.quantisnow.com/options/INBX
- SEC 8-K filings only: https://www.quantisnow.com/company/INBX/8-k
- RSS and alerts for INBX: https://www.quantisnow.com/docs/rss-feeds.md
